Ariel Savina
Boulogne-billancourt, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Journal: Nature cancer
Published: February 04, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 19, 2021
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Journal: Anti-cancer drugs
Published: January 03, 2020
IDO Targeting in Sarcoma: Biological and Clinical Implications.
Journal: Frontiers in immunology
Published: October 25, 2019
Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles.
Journal: Scientific reports
Published: September 30, 2019
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Journal: Frontiers in immunology
Published: March 22, 2019
Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 26, 2019
Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells.
Journal: Cancers
Published: January 11, 2019
Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function.
Journal: Frontiers in immunology
Published: December 17, 2018
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
Journal: International journal of nanomedicine
Published: November 15, 2018
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.
Journal: Theranostics
Published: August 08, 2018
Last Updated: 09/26/2026